Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Michael Douglas Taylor net worth and biography

Michael Taylor Biography and Net Worth

Director of Deciphera Pharmaceuticals

Dr. Michael Douglas Taylor serves as Director of the Company. He is an Operating Partner with Mission BioCapital, an early-stage life science venture fund. Dr. Taylor served as our President and Chief Executive Officer from March 2014 until his retirement as Chief Executive Officer in March 2019. Dr. Taylor served as Senior Advisor to Deciphera from March 2019 through September 2019. Prior to joining Deciphera, Dr. Taylor was Chief Executive Officer of Ensemble Therapeutics, Corp., a small molecule drug discovery company, from July 2007 to October 2013. Prior to joining Ensemble, Dr. Taylor was Senior Vice President for Pfizer Inc.’s Global R&D division and served as Vice President, Drug Development at Warner-Lambert/Parke-Davis, where he led early and late-stage development projects across multiple therapeutic areas, including Lipitor® and Neurontin®. Dr. Taylor has authored or co-authored 65 manuscripts and published abstracts and is co-inventor on eight patents. Dr. Taylor holds a Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo School of Pharmacy, was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania, and holds a B.S. magna cum laude in chemistry from the University of South Florida.

What is Michael Douglas Taylor's net worth?: The estimated net worth of Michael Douglas Taylor is at least $117,360.00 as of April 1st, 2021. Dr. Taylor owns 8,000 shares of Deciphera Pharmaceuticals stock worth more than $117,360 as of April 20th. This net worth approximation does not reflect any other assets that Dr. Taylor may own. Learn More about Michael Douglas Taylor's net worth.
How do I contact Michael Douglas Taylor?: The corporate mailing address for Dr. Taylor and other Deciphera Pharmaceuticals executives is 200 SMITH STREET, Waltham MA, 02451. Deciphera Pharmaceuticals can also be reached via phone at (781) 209-6400 and via email at [email protected]. Learn More on Michael Douglas Taylor's contact information.
Has Michael Douglas Taylor been buying or selling shares of Deciphera Pharmaceuticals?: Michael Douglas Taylor has not been actively trading shares of Deciphera Pharmaceuticals during the past quarter. Most recently, Michael Douglas Taylor sold 8,000 shares of the business's stock in a transaction on Thursday, April 1st. The shares were sold at an average price of $45.57, for a transaction totalling $364,560.00. Following the completion of the sale, the director now directly owns 8,000 shares of the company's stock, valued at $364,560. Learn More on Michael Douglas Taylor's trading history.
Who are Deciphera Pharmaceuticals' active insiders?: Deciphera Pharmaceuticals' insider roster includes James Bristol (Director), Daniel Flynn (Insider), Thomas Kelly (CFO), Matthew Sherman (EVP), and Michael Taylor (Director). Learn More on Deciphera Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Deciphera Pharmaceuticals?: In the last year, Deciphera Pharmaceuticals insiders bought shares 2 times. They purchased a total of 21,000 shares worth more than $291,260.00. In the last year, insiders at the sold shares 9 times. They sold a total of 37,550 shares worth more than $470,122.61. The most recent insider tranaction occured on January, 16th when EVP Matthew L Sherman sold 2,435 shares worth more than $35,234.45. Insiders at Deciphera Pharmaceuticals own 4.4% of the company. Learn More about insider trades at Deciphera Pharmaceuticals.
Information on this page was last updated on 1/16/2024.

Michael Douglas Taylor Insider Trading History at Deciphera Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2021	Sell	8,000	$45.57	$364,560.00	8,000
1/4/2021	Sell	19,000	$56.45	$1,072,550.00	19,000
12/1/2020	Sell	19,000	$60.90	$1,157,100.00	19,000
7/6/2020	Sell	27,544	$55.22	$1,520,979.68	49,211
7/2/2020	Sell	48,245	$56.69	$2,735,009.05	49,211
4/28/2020	Sell	25,000	$56.90	$1,422,500.00	25,000
4/17/2020	Sell	23,892	$46.67	$1,115,039.64	23,892
4/14/2020	Sell	1,108	$46.71	$51,754.68	1,108
4/1/2020	Sell	75,000	$37.57	$2,817,750.00	75,000
1/3/2020	Sell	31,422	$57.31	$1,800,794.82	93,578
9/11/2019	Sell	22,500	$34.97	$786,825.00
9/3/2019	Sell	7,500	$36.26	$271,950.00	7,500
8/13/2019	Sell	22,500	$40.77	$917,325.00
2/19/2019	Sell	9,431	$28.85	$272,084.35
2/13/2019	Sell	2,866	$28.00	$80,248.00
2/5/2019	Sell	1,700	$28.01	$47,617.00

Michael Douglas Taylor Buying and Selling Activity at Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Company Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $14.67

$14.05

$14.69

50 Day Range

MA: $15.70

$14.23

$17.36

2 Week Range

Now: $14.67

$9.90

$17.73

Volume

394,292 shs

Average Volume

524,756 shs

Market Capitalization

$1.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad